Among the goals of an optimal gene transfer system are a predictably high efficiency of transfer and the ability to confer stable gene expression. An additional benefit of strategies designed to target tumor or effector cells could be the induction of a bystander effect. Although tumor killing by the bystander effect in vivo has been obtained in several types of malignant tumors, it has not been reported for T lymphomas. The goals of this work were to determine the stability of the expression of the herpes simplex virus type-1 thymidine kinase and the low-affinity receptor for nerve growth factor truncated of its intracellular domain (⌬LNGFR) genes inserted in a murine T lymphoma; in addition, we sought to determine whether a bystander effect (direct or indirect) was present after treatment of the transduced tumor with ganciclovir. This study demonstrates a high level of stable expression of both genes in the T lymphoma in vitro and in vivo. However, we could not detect direct or indirect bystander effects in vivo mediated by the herpes simplex virus thymidine kinase/ganciclovir system in this tumor of lymphocyte origin. This is the first report to investigate bystander effects in vivo on a T-cell lineage tumor; in addition, this report has implications for the therapeutic transfer of non-transformed, antigen-specific T cells in vivo. Cancer Gene Therapy (2000) 7, 954 -962
A n emerging strategy in many ongoing and proposed gene therapy trials for human cancer involves the transfer of the herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells, rendering them susceptible to the cytotoxic effects of ganciclovir (GCV). Another application of gene therapy is to use suicide gene-transduced T cells to induce a graft versus leukemia effect after allogeneic stem cell transplantation and thus control or abrogate graft versus host disease, if it occurs, by the administration of GCV. Lymphocytes have several features that make them potentially attractive cellular vehicles for gene therapy, 1 such as their availability from the peripheral blood and the ease of in vitro manipulation. Stable HSV-tk expression in vivo is of crucial importance in this strategy if destruction of the transduced cells is to be achieved several months after their administration.
In some cell types, part of the therapeutic effect of this suicide gene is derived from a bystander effect (i.e., after exposure to GCV, HSV-tk-expressing cells can also induce cell death in neighboring cells, which do not themselves express HSV-tk). In vitro, the transfer of phosphorylated GCV metabolites from tk ϩ to tk Ϫ cells through gap junctions has been demonstrated for some cell types and is assumed to account for this bystander effect. [2] [3] [4] [5] [6] [7] Other mechanisms, such as the transfer of an apoptotic signal through the uptake of apoptotic bodies, might also play a role. 4, 8, 9 In vivo, the bystander effect may also be immunemediated, 10 raising the possibility that this effect can be exerted at a distance, and thus influence the development of non-transduced tumors. 11, 12 Gillio Tos et al 13 have documented a bystander effect in vitro using mixed-culture experiments in which tumor necrosis factor-␣-transduced and non-transduced ST4 cells (a human lymphoma T-cell line) were coincubated. However, Tiberghien et al 14 transduced primary T cells with a retroviral vector containing the HSV-tk and neo r genes and did not detect any bystander effect in vitro. Investigation of bystander effects using T cells in vivo has not been described.
In the present work, we used the retroviral vector SFCMM-3, which contains both HSV-tk and the lowaffinity receptor for nerve growth factor truncated of its intracellular domain (⌬LNGFR) gene. This vector was described by Verzeletti et al 15 as poorly immunogenic and able to confer high GCV sensitivity to transduced human lymphocytes in vitro. Our results demonstrate that the SFCMM-3 vector can be used to efficiently transduce a murine T lymphoma, RMA. Using this system, we demonstrate the stability of expression of the transduced genes both in vitro and in vivo. However, we show that no bystander effect, either direct or indirect, is produced by the tk-transduced cells in vitro or in vivo in this particular murine tumor model.
MATERIALS AND METHODS

Cell lines and vectors
RMA is a Rauscher virus-induced T-cell lymphoma of C57BL/6 origin. 16 This cell line (kindly provided by Dr. H. Stauss, Hammersmith Hospital, London, UK) was maintained in RPMI 1640 medium plus 10% fetal calf serum, 100 M L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin (complete medium). We used both the retroviral vector SFCMM-3 15 carrying the HSV-tk gene transcribed from the long terminal repeat and the ⌬LNGFR marker gene transcribed from an internal simian virus 40 early promoter. The SFCMM-3 producer cell line (a kind gift of Prof. C. Bordignon, Milan, Italy) was cultured in Dulbecco's modified Eagle's medium with 10% fetal calf serum. Supernatant containing the viral vector particles (titer: 1 ϫ 10 6 cells/mL) was collected and frozen in aliquots at Ϫ80°C. Murine anti-human LNGFR monoclonal antibody 20.4 was obtained from the American Type Culture Collection (Manassas, Va).
Transduction of RMA cells with retroviral vector SFCMM-3
RMA cells (1 ϫ 10 6 cells) were plated in complete medium in 10-cm 2 tissue culture plates for 24 hours. The culture medium was then replaced with 2 mL of SFCMM-3 retroviral vector supernatant and 8 g/mL polybrene for 2 hours. Subsequently, the supernatant was replaced with complete medium. This procedure was repeated daily for 2 additional consecutive days. The cells were then cultured for 48 hours in complete medium and selected using a immunomagnetic system. Immunoselection was performed by incubating the cells with the anti-LNGFR monoclonal antibody and selecting with goat anti-mouse immunoglobulin G-coated magnetic beads (MiniMACS; Miltenyi Biotech, Sunnyvale, Calif). Transduction efficiencies were quantified as the proportion of cells expressing ⌬LNGFR at 2 days postinfection. Selected cells were cloned by limiting dilution and ⌬LNGFR expression was confirmed by flow cytometry using the anti-LNGFR antibody.
In vitro GCV sensitivity assay
The effect of GCV on DNA replication was quantified using a [ 3 H]thymidine incorporation proliferation assay. Cells (5 ϫ 10 3 ) were plated in medium containing different concentrations of GCV (0 -100 g/mL) (Cymevene, Roche, Germany). After 60 hours of culture, 1 Ci of [ 3 H]thymidine was added to the cells for another 14 hours, after which time they were harvested and counted. The effect of GCV on cell proliferation is expressed as the percentage of thymidine incorporation measured in non-treated cultures grown under the same conditions.
In vitro analysis of a bystander effect
The presence or absence of bystander killing was determined by mixing transduced (tk ϩ ) and non-transduced (tk Ϫ ) cells at various ratios (from 0% to 100% transduced). The cells were then plated in 24-well plates at 1 ϫ 10 6 cells/well in 2 mL of complete medium and 0.8 g/mL GCV and incubated for 3 days; after incubation, viable cells were counted using the trypan blue dye exclusion test.
In vivo studies
Female C57BL/6 mice of 8 to 12 weeks of age were maintained according to UK Home Office guidelines. Groups of 15 mice received a subcutaneous (s.c.) injection of 10 5 , 2 ϫ 10 5 , 5 ϫ 10 5 , or 1 ϫ 10 6 non-transduced RMA tumor cells in one flank and the same dose of transduced RMA cells in the contralateral flank. For each group, five mice were treated with phosphate-buffered saline (PBS), five mice were treated with GCV starting on the day of the injection (prophylactic treatment), and five mice were treated with GCV after the development of tumors (8 -10 days postinjection). Experiments were repeated on one subsequent occasion using 2 ϫ 10 5 cells, as this dose was felt to be one of the most informative (see below). For each cell dose, additional groups of 10 mice received transduced or non-transduced cells in both flanks and were treated with PBS (n ϭ 5) or GCV (n ϭ 5) from the time of infection as described above. Another group of 10 mice was injected with 2 ϫ 10 5 cells comprising a mixture of nontransduced and transduced cells in both flanks (ratio of transduced to non-transduced cells was 1:3 in one flank and 1:5 in the other flank): Five mice were treated with GCV starting on the day of the injection; the other five mice were treated with PBS.
GCV was administered intraperitoneally (i.p.) at 20 mg/kg/ day. Mice were monitored daily, and the tumor size for each individual mouse was determined. Tumor volumes were calculated according to the following formula: V ϭ a ϫ b 2 /2, where a equals the largest diameter and b equals the smallest diameter; the largest section of the tumor was measured.
Animals were sacrificed at different time intervals after cell injections; next, tumors and other tissues (spleen, liver, bone marrow, lymphatic nodes, peripheral blood, and kidney) were analyzed for the presence and expression of the exogenous genes.
Southern blot analysis
High molecular weight DNA was prepared, digested with EcoRI, electrophoresed through a 0.8% agarose gel, and transferred to a nylon filter (Hybond-N; Amersham, Little Chalfont, UK) as described by the manufacturer. The filter was probed with a 32 P-labeled EcoRI-KhoI fragment isolated from SFCMM-3 corresponding to the entire HSV-tk gene.
Detection of the transgene in mouse tissues by polymerase chain reaction (PCR)
Genomic DNA was isolated from mouse tissues using a Qiagen DNA extraction kit (Blood Kits; Qiagen, UK). PCR amplification of a 753-bp fragment of the integrated SFCMM-3 vector spanning the 3Јend of the tk and the 5Ј end of the ⌬LNGFR cassettes was done with the following primers: 5Ј-TTGCAG-CACTCACCGCTGTGTGT-3Ј (forward) and 5Ј-CCATG-CACGTCTTTATCCTGGAT-3Ј (reverse). PCRs were performed in a 20-L reaction mixture containing 50 ng of genomic DNA using standard reaction conditions. Thermocycling parameters were 31 cycles of incubation at 100°C (10 seconds), 97°C (20 seconds), 62°C (25 seconds), 64°C (25 seconds), 78°C (10 seconds), and 73°C (50 seconds) followed by a final 10-minute extension at 72°C. All PCR products were visualized by electrophoresis on ethidium bromide-stained 1% agarose gels.
Statistical analysis
Tumor volumes were expressed as the mean Ϯ SD. Statistical analyses of the data were carried out using the analysis of variance test. Differences were considered significant when P values were Ͻ.05.
RIVAS, CHANDLER, MELO, ET AL: LACK OF A BYSTANDER EFFECT IN TK ϩ MURINE T-LYMPHOMA CELLS
RESULTS
Transduction and cloning RMA cells were transduced with the SFCMM-3 recombinant retrovirus containing both the tk and the ⌬LNGFR genes. The proportion of transduced RMA cells after two rounds of gene transfer was of the order of 17-20%. After selection, in excess of 70 -80% of the cells expressed ⌬LNGFR. Selected cells were cloned by limiting dilution and analyzed with a fluorescence-activated cell sorter (FACS) for cell surface expression of ⌬LNGFR (Fig 1A) . The sensitivity of these clones to GCV was tested using a proliferation assay in which transfer of the HSV-tk gene and GCV sensitivity were confirmed in vitro. Exposure of transduced cells to as little as 0.8 g/mL GCV induced an 80% decrease in [ 3 H]thymidine incorporation but did not affect non-transduced cells (Fig 1C) . In the absence of the drug, the proliferation of the transduced and non-transduced cells was similar, indicating that the introduced genes did not affect the replicative capacity of the cells (data not shown). Southern blot analysis of EcoRI-digested DNA isolated from these cloned cells and hybridized with a probe corresponding to the entire tk gene revealed a single band representing a single viral integration per cell (data not shown).
Stability of gene expression
Transduced clones were maintained in culture over 6 months and during this time, the stability of expression of both the ⌬LNGFR and the tk genes was observed in vitro, as assessed by FACS analysis and proliferation assays in the presence of GCV, respectively (Fig 1, B and  D) .
In vitro bystander effect
To investigate a possible in vitro bystander effect, we examined the rate of cell death after the addition of GCV to a mixture of transduced and non-transduced RMA cells (0, 25, 50, 75, or 100% transduced cells). As illustrated in Figure 2 , the extent of cell killing was directly correlated with the percentage of tk-transduced cells in the mixture, providing no evidence for an HSV-tk-mediated bystander effect in RMA cells.
In vivo studies
Mice injected s.c. with transduced and non-transduced RMA cells were observed for the development of tumors and their regression in response to GCV administration. As expected, PBS-treated animals developed bilateral tumors; no significant differences were observed between the size of the tk ϩ and tk Ϫ tumors at different times (data not shown). Prophylactic i.p. administration of GCV partially prevented tumor development after s.c. injection of 1 or 2 ϫ 10 5 tk ϩ -transduced RMA cells per flank (60% and 40%, respectively, of the mice in these two groups did not develop tumors); in addition, the overall growth of the established tumors was slow, whereas the same effect was not observed after PBS administration (Fig 3) . This effect of GCV was less evident at the higher cell doses of 5 ϫ To assess the intratumoral bystander effect in our model, we generated single s.c. lymphoma tumors using mixtures of tk ϩ and tk Ϫ RMA cells in various proportions; mice were treated prophylactically with GCV or PBS. The mean volume of mixed tk Ϫ and tk ϩ tumors comprising 20% or 33% tk ϩ cells in mice treated with GCV was not significantly reduced compared with mice treated with PBS. This result indicated the absence of a local bystander effect (Fig 4) .
To determine the presence of a putative distant bystander effect, mice were given s.c. injections of tk ϩ RMA cells in one flank and tk Ϫ RMA cells in the contralateral flank and then received either prophylactic GCV or PBS. Therefore, the resulting tumors were not physically contiguous. At each cell dose tested, neither the rate of growth nor the overall size of the nontransduced tumors differed significantly between GCV or PBS treatments (Fig 5) , indicating the absence of a distant bystander effect.
Similar results were obtained when therapeutic administration of GCV was started after the development of palpable tumors, between 8 and 10 days after the injection of 1, 2, 5, or 10 ϫ 10 5 cells in each flank. Although complete regression of the transduced tumors was not achieved, subsequent growth was reduced compared with those mice treated with PBS (data not shown). No significant differences in the growth of the non-transduced tumors after therapeutic GCV or PBS treatment were detected (data not shown).
Ex vivo experiments
Tumor cells were re-isolated at different times from solid tumors growing in mice treated with PBS after injection of transduced RMA cells, and the expression of the inserted genes was measured. Both ⌬LNGFR and tk genes were expressed at levels that were similar to those found previously by FACS analysis (Fig 6A) and by proliferation assays in the presence of different GCV concentrations (Fig 6B) , indicating that growth of the transduced cells in vivo did not alter expression of the transgenes over the period of observation.
To examine the possibility that retroviral particles may have reached other vascularized organs, several tissues from recipient mice were removed at different times after injection and tested by PCR for the presence of the inserted genes. Analysis of peripheral blood, bone marrow, spleen, liver, kidney, and lymphatic nodes did not show any evidence of the exogenous genes (Fig 7) . Only transduced tumor cells contained PCR products corresponding to the inserted genes, suggesting that retroviral infection was restricted to the tumor adjacent to the injection site.
DISCUSSION
The application of gene therapy via transduced T lymphocytes is a promising approach for the treatment of certain human diseases. One possible application is the use of transduced T cells to control or abrogate graft versus host disease following donor lymphocyte infusion after allogeneic stem cell transplantation. The candidate cells must be capable of efficient transduction and stable expression of the transferred genes and tolerant of the selection procedures used to enrich for cells expressing the introduced genes. In addition, the modified cells must survive once reintroduced into the host, and the gene-insertion procedure should not significantly interfere with the functional properties or phenotype of the cells. The experiments described here, using the RMA cell line derived from a T-cell lymphoma, address questions regarding the longevity and activity of tk gene expression in cells of this lineage.
Unlike mammalian cell tk, HSV-tk is able to efficiently catalyze the phosphorylation of the relatively nontoxic anti-herpetic drug GCV into the highly toxic metabolite, GCV-triphosphate, 17 which as a substrate for DNA replication can cause premature chain termination and lead to cell death. 18 One feature of the gene transfer/prodrug approach is the generation of bystander cytotoxicity leading to the death of untransduced cells adjacent to genetically modified cells. A number of studies suggest that this bystander effect plays a role in overcoming the limitations of gene transfer (i.e., the failure to transduce all the cells targeted). Several potential mechanisms have been proposed to mediate this phenomenon. Freeman et al 8 hypothesized that the uptake of phosphorylated GCV by bystander cells occurs via endocytosis of apoptotic vesicles, originating from the neighboring tk-transduced cells and containing the toxic drug. However, increasing evidence suggests that the bystander effect is mediated via gap junctions that allow phosphorylated GCV to translocate from tk ϩ to tk Ϫ cells intercellularly. 2, 19 Cirenei et al 20 suggested that the release of apoptotic vesicles caused by GCV-mediated death can cooperate with the presence of gap junctions to spread GCV-triphosphate to surrounding cells. Although the bystander effect can be observed in vitro, an immune component might additionally be involved in some tumor models, because this phenomenon is impaired or absent in immunocompromised animals. 4 , 21 Mullen et al 22 have hypothesized that the tk-modified tumors in animals treated with GCV undergo necrosis, and that this process enhances the presentation of antigens associated with the tumor cell. Another possibility is that the in vivo mechanism of the bystander effect is due to alterations in the tumor microenvironment secondary to infiltration of leukocytes and to the subsequent release of cytokines, which result in tumor regression by a nonspecific mechanism. 23 In vivo antitumoral gene therapy using the HSV-tk gene and GCV has been reported to elicit an important intratumoral bystander effect. The elimination of a whole tumor when only a fraction of its cells express tk has been described in murine colon adenocarcinoma, 24 in a human melanoma cell line, 25, 26 in human myeloma cell lines, 27 in glioma cells in the brain, 28, 29 and in a murine sarcoma cell model. 8 Distant bystander effects have been observed between distant hepatic tumors, 11 including those generated by the poorly immunogenic DHDK12 cell line, 30 and in human myeloma cell lines. 27 Our studies show that the in vitro growth characteristics of the tk ϩ derivatives of the RMA cells are similar to those of their parental cells. However, sensitivity to GCV toxicity is conferred onto these derivatives. In our study, the gene insertion, selection, and culture expansion did not alter the growth characteristics of the T cells in vitro, in agreement with previous results obtained by Culver et al. 1 Expression of the transduced genes was found to be stable in RMA cells cultured for a period in excess of 6 months, similar to that reported by others using different T-cell lines. 1, 14, 31 Our studies also demonstrated the absence of a bystander effect in vitro using this murine T lymphoma, similar to the results obtained by Tiberghien et al 14 in primary human T lymphocytes transduced with the tk gene.
In our in vivo experiments, transduced and nontransduced cells also showed similar growth characteristics in mice in the absence of GCV treatment, indicating that integration of the provirus does not alter the tumorigenic behavior of the cells and that transduction and selection/cloning procedures do not induce an immune response to the tumor in the mice.
Our results showed that tumors developing from RMA cells after the injection of mixed transduced and non-transduced cells were not significantly affected by treatment with GCV, implying the absence of any local bystander effect. Similarly, the growth of non-transduced cells in the presence of transduced cells in the same mouse was independent of the type of treatment (PBS or GCV) or of the treatment protocol (prophylactic or therapeutic), demonstrating the absence of any distant bystander effect.
In systems in which an antitumoral bystander effect is observed, the simplest explanation for antitumoral immunity after GCV treatment of tk ϩ cells is that tumor antigens from dead cells are presented to the immune system. If this is the case, one would predict that a similar immunological effect could be produced by injection of lethally irradiated tumor cells. RMA cells have been shown to induce immunological effects when treated with mitomycin C and injected s.c. 32 However, use of the TK/GCV system with RMA cells does not seem to induce this immunological effect, because we could not detect any specific bystander effect.
The results reported by Consalva et al 33 using the cytosine deaminase system and by others examining the use of TK in the C57BL/6 melanoma 34 and BALB/c fibrosarcoma 23, 35 are more consistent with a different hypothesis. Prodrug-induced cell death in vitro may be mediated by apoptosis. 8, 36, 37 However, it has also been reported that in vivo prodrug treatment of suicide genemodified tumors produces tumor necrosis, and its inflammatory response may break down the immunological isolation of a tumor 22 and increase the opportunity to elicit a tumor specific response. A study of the mechanism by which RMA cells die after GCV treatment will be necessary to explain the complete absence of bystander effect in our system.
The findings of this study using HSV-tk transduction of a T lymphoma are therefore relevant to two different clinical scenarios. The first is the treatment of lymphomas by transducing tumor cells ex vivo, followed by reinfusion and administration of GCV, where the absence of bystander effects mitigates against therapeutic benefit. The second is the use of HSV-tk-transduced T cells specific for antigens expressed on leukemia cells in donor lymphocyte infusions, where the absence of bystander effects may be an advantage because the selective survival of the quiescent cells may be necessary for the maintenance of the graft versus leukemia effect.
